Navigation Links
Statin use associated with reduction in prostate specific antigen levels
Date:10/28/2008

Use of cholesterol-lowering statins is associated with a statistically significant decline in prostate specific antigen (PSA) levels, according to a report in the October 28 online issue of the Journal of the National Cancer Institute.

Previous studies examined whether statin use was associated with a reduction in prostate cancer risk. The results, however, have been inconsistent. Few studies have examined the association between statins and PSA level.

In the current study, Stephen Freedland, M.D., of the Durham Veterans Affairs Medical Center and Duke University School of Medicine in Durham, N.C., and colleagues examined computerized medical records of 1,214 men who were prescribed statins between 1990 and 2006 at the Durham Veterans Affairs Medical Center. To learn whether statin use was associated with changes in PSA, the investigators compared PSA values taken up to two years before initiation of statin therapy and PSA values measured within one year after initiation of statin use.

The researchers saw a median decline in PSA of 4.1% and a 27.5% median decline of low-density lipoprotein (LDL) in the participants, both of which were statistically significant changes. Moreover, men with higher initial PSA levels had, on average, larger declines after starting on statins than men who had low initial PSA levels; the PSA declines correlated with the magnitude of the LDL decrease. Specifically, among men most likely to be under consideration for prostate biopsy (pre-statin PSA levels ≥2.5 ng/mL) those with the biggest declines (highest quartile) in LDL after starting a statin experienced a 17% decline in PSA. The decline in PSA also strongly correlated with the dose of statin and this dose-dependency was associated with PSA even after the researchers accounted for drop in LDL.

"The PSA declines with statin use that we observed may represent objective evidence of statins influence on prostate biology in support of epidemiological studies suggesting statins reduce overall or advanced prostate cancer risk. More importantly, this PSA decline, if confirmed in future studies, may complicate prostate cancer screening because cancers may be missed due to the lower PSA levels, and this fact should be kept in mind when evaluating men taking statins," the authors write. The impact of such a change on prostate cancer mortality, the authors note, is unclear because there is no level 1 evidence to indicate that PSA screening lowers prostate cancer mortality.

In an accompanying editorial, Ian Thompson, M.D., of the University of Texas Health Science Center in San Antonio and colleagues suggest that the new data should be interpreted with caution. While it is possible that statins alter prostate biology, a reduction in PSA does not necessarily correlate with a reduction in cancer risk. Moreover, the observational study design used by Freedland and colleagues could lead to unintended bias in the results. Finally, although the 4.1% drop in median PSA is statistically significant, it may not be clinically meaningful.

Therefore, further studies are needed to better understand the impact of statins on a prostate cancer, the editorialists conclude. "If statins do lower PSA, only a randomized trial with histological endpoints can determine whether statins affect a man's risk of prostate cancer," they write.


'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Continued Statin Use Boosts Post-Stroke Outcomes
2. Stopping Statins After Stroke Doubles Death Risk
3. Research to shed new light on how statins benefit heart patients
4. A New Study Links High Volume Pain Pumps with the Devastating and Painful Loss of Cartilage Following Arthroscopic Shoulder Surgery
5. Statin Benefits Persist After Treatment Stops
6. Statins reduce loss of function, keeping old lungs young - even in smokers
7. Better Prostate Cancer Survival for Men Taking Statins
8. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
9. Congress called on to replace devastating cuts in Medicare reimbursements by ACP
10. Statins After Bypass Lower Stroke Risk
11. Burn injuries take devastating toll on nations children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: